Emilee N. Kotnik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Emilee N. Kotnik has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Carolyn K. McCourt
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine in St Louis, St Louis, Missouri
70 shared publications - David Michael Mutch
Department of Human Health and Nutritional Sciences University of Guelph Guelph Ontario Canada
70 shared publications - Lindsay M. Kuroki
Washington University School of Medicine in St. Louis, Obstetrics and Gynecology, St. Louis, MO, US
70 shared publications - Mary M. Mullen
Washington University School of Medicine in St. Louis
70 shared publications - Premal H. Thaker
Washington University School of Medicine, St. Louis, MO, USA
70 shared publications - Andrea R. Hagemann
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri
69 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 expression and platinum chemotherapy response in vitro and in patient tumors
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Flow diagram of HGSOC patient-derived samples used for RAD51 foci assay
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
RAD51 scores in BRCA mutated tumors shows correlation with survival and protein integrity
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE validation cohort
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
γH2AX score in established and patient-derived ovarian cancer cell lines and patient-derived organoids
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer cells
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of patient-derived ovarian cancer cells
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE discovery cohort
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
Patient characteristics of FFPE discovery cohort
- Open Access
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
Supplemental Table S1, S2, S3.
- 15 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response
Supplemental Table S1, S2, S3.